Edition:
United Kingdom

Paratek Pharmaceuticals Inc (PRTK.OQ)

PRTK.OQ on NASDAQ Stock Exchange Global Market

20.40USD
8:59pm GMT
Change (% chg)

$-0.05 (-0.24%)
Prev Close
$20.45
Open
$20.35
Day's High
$20.55
Day's Low
$19.85
Volume
61,479
Avg. Vol
129,747
52-wk High
$29.00
52-wk Low
$12.65

Latest Key Developments (Source: Significant Developments)

Paratek Pharmaceuticals Q3 loss per share $0.77
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Paratek Pharmaceuticals Inc ::Paratek Pharmaceuticals reports third quarter 2017 financial results, remains on track to complete NDA submissions in first quarter of 2018.Q3 loss per share $0.77.Q3 earnings per share view $-0.94 -- Thomson Reuters I/B/E/S.Paratek Pharmaceuticals - ‍cash, cash equivalents and marketable securities sufficient to fund operating expenses, Capex requirements through Q2 2019​.  Full Article

Paratek initiates phase 3 study of oral-only Omadacycline in ABSSSI
Monday, 15 Aug 2016 

Paratek Pharmaceuticals Inc :Initiates phase 3 study of oral-only Omadacycline in ABSSSI.  Full Article

Paratek Pharma reports Q2 loss per share of $1.69
Thursday, 4 Aug 2016 

Paratek Pharmaceuticals Inc : Q2 loss per share $1.69 . Q2 earnings per share view $-1.66 -- Thomson Reuters I/B/E/S . Paratek pharmaceuticals, inc. Reports second quarter 2016 financial and operating results .Phase 3 registration study evaluating omadacycline for treatment of cabp remains on track to report as early as q3 of 2017.  Full Article

Paratek announces proposed public offering of common stock
Monday, 20 Jun 2016 

Paratek Pharmaceuticals Inc : Says commenced proposed public offering of 3.8 million shares of its common stock . Intends to use net proceeds from offering to fund its planned clinical studies of omadacycline .Paratek announces proposed public offering of common stock.  Full Article

Paratek says Omadacycline met primary, secondary efficacy outcomes designated by FDA and EMA
Thursday, 16 Jun 2016 

Paratek Pharmaceuticals Inc : Two deaths occurred during the study, both in the linezolid group . Iv to oral omadacycline was generally safe and well tolerated .Omadacycline met primary, secondary efficacy outcomes designated by fda and ema in phase 3 study in acute bacterial skin infections.  Full Article

Paratek Pharmaceuticals receives FDA affirmation for design of proposed omadacycline phase 3 study
Tuesday, 10 May 2016 

Paratek Pharmaceuticals Inc : Receives FDA affirmation for design of proposed omadacycline oral only skin infection phase 3 study: opportunity to accelerate access to broader oral-only markets . FDA affirms chosen comparator, primary endpoint for Phase 3 study . Study, if conducted, would initiate following reporting of top-line data from IV-to-Oral ABSSSI Phase 3 study . Potential to include oral-only skin study in projected NDA filing in first half of 2018 .Top-line data from Phase 3 registration study for CABP is expected as early as Q3 of 2017.  Full Article

BRIEF-Paratek Pharmaceuticals Q3 loss per share $0.77

* Paratek Pharmaceuticals reports third quarter 2017 financial results, remains on track to complete NDA submissions in first quarter of 2018